Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.
Identifieur interne : 001C12 ( PubMed/Corpus ); précédent : 001C11; suivant : 001C13Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.
Auteurs : David D. Dore ; Amal N. Trivedi ; Vincent Mor ; Joseph H. Friedman ; Kate L. LapaneSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antipsychotic Agents (adverse effects), Antipsychotic Agents (classification), Antipsychotic Agents (therapeutic use), Case-Control Studies, Confidence Intervals, Databases, Factual (statistics & numerical data), Female, Fractures, Bone (chemically induced), Humans, Logistic Models, Male, Medicaid (statistics & numerical data), Middle Aged, Odds Ratio, Parkinsonian Disorders (drug therapy), Risk Assessment, Risk Factors, United States.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , classification : Antipsychotic Agents.
- chemical , therapeutic use : Antipsychotic Agents.
- geographic : United States.
- chemically induced : Fractures, Bone.
- drug therapy : Parkinsonian Disorders.
- statistics & numerical data : Databases, Factual, Medicaid.
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Confidence Intervals, Female, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Risk Assessment, Risk Factors.
Abstract
Our objective was to estimate the effect of atypical antipsychotics (AAs) on the rate of fractures in a parkinsonism population. We conducted an age- and state-matched nested case-control study in five states (CA, FL, NY, OH, IL) using the Medicaid analytic extract from 2001 to 2002. Eligible participants had a diagnosis of parkinsonism, excluding persons with secondary parkinsonism, bone cancer, bone infections, schizophrenia, schizoaffective disorder, and those who used conventional antipsychotics. The primary outcome was the occurrence of a fracture of the femur, ankle, fibula, tibia, humerus, radius, or ulna (N = 851). Risk-set sampling defined controls (N = 4220). We used conditional-logistic regression to derive adjusted odds ratios (AOR) and 95% confidence intervals of the association between fracture and use of quetiapine, risperidone, or olanzapine in the 60 days before the index date compared to nonuse. After adjustment for confounding, use of quetiapine (AOR 2.4; 95% CI 1.5-3.8), risperidone (AOR 1.2; 95% CI 0.9-1.7), or olanzapine (AOR 1.7; 95% CI 1.2-2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism.
DOI: 10.1002/mds.22679
PubMed: 19645066
Links to Exploration step
pubmed:19645066Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.</title><author><name sortKey="Dore, David D" sort="Dore, David D" uniqKey="Dore D" first="David D" last="Dore">David D. Dore</name><affiliation><nlm:affiliation>i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts, USA. david.dore@i3drugsafety.com</nlm:affiliation></affiliation></author><author><name sortKey="Trivedi, Amal N" sort="Trivedi, Amal N" uniqKey="Trivedi A" first="Amal N" last="Trivedi">Amal N. Trivedi</name></author><author><name sortKey="Mor, Vincent" sort="Mor, Vincent" uniqKey="Mor V" first="Vincent" last="Mor">Vincent Mor</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author><author><name sortKey="Lapane, Kate L" sort="Lapane, Kate L" uniqKey="Lapane K" first="Kate L" last="Lapane">Kate L. Lapane</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22679</idno><idno type="RBID">pubmed:19645066</idno><idno type="pmid">19645066</idno><idno type="wicri:Area/PubMed/Corpus">001C12</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.</title><author><name sortKey="Dore, David D" sort="Dore, David D" uniqKey="Dore D" first="David D" last="Dore">David D. Dore</name><affiliation><nlm:affiliation>i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts, USA. david.dore@i3drugsafety.com</nlm:affiliation></affiliation></author><author><name sortKey="Trivedi, Amal N" sort="Trivedi, Amal N" uniqKey="Trivedi A" first="Amal N" last="Trivedi">Amal N. Trivedi</name></author><author><name sortKey="Mor, Vincent" sort="Mor, Vincent" uniqKey="Mor V" first="Vincent" last="Mor">Vincent Mor</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H" last="Friedman">Joseph H. Friedman</name></author><author><name sortKey="Lapane, Kate L" sort="Lapane, Kate L" uniqKey="Lapane K" first="Kate L" last="Lapane">Kate L. Lapane</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antipsychotic Agents (adverse effects)</term><term>Antipsychotic Agents (classification)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Case-Control Studies</term><term>Confidence Intervals</term><term>Databases, Factual (statistics & numerical data)</term><term>Female</term><term>Fractures, Bone (chemically induced)</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Medicaid (statistics & numerical data)</term><term>Middle Aged</term><term>Odds Ratio</term><term>Parkinsonian Disorders (drug therapy)</term><term>Risk Assessment</term><term>Risk Factors</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fractures, Bone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Databases, Factual</term><term>Medicaid</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Confidence Intervals</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Risk Assessment</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Our objective was to estimate the effect of atypical antipsychotics (AAs) on the rate of fractures in a parkinsonism population. We conducted an age- and state-matched nested case-control study in five states (CA, FL, NY, OH, IL) using the Medicaid analytic extract from 2001 to 2002. Eligible participants had a diagnosis of parkinsonism, excluding persons with secondary parkinsonism, bone cancer, bone infections, schizophrenia, schizoaffective disorder, and those who used conventional antipsychotics. The primary outcome was the occurrence of a fracture of the femur, ankle, fibula, tibia, humerus, radius, or ulna (N = 851). Risk-set sampling defined controls (N = 4220). We used conditional-logistic regression to derive adjusted odds ratios (AOR) and 95% confidence intervals of the association between fracture and use of quetiapine, risperidone, or olanzapine in the 60 days before the index date compared to nonuse. After adjustment for confounding, use of quetiapine (AOR 2.4; 95% CI 1.5-3.8), risperidone (AOR 1.2; 95% CI 0.9-1.7), or olanzapine (AOR 1.7; 95% CI 1.2-2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19645066</PMID><DateCreated><Year>2009</Year><Month>11</Month><Day>03</Day></DateCreated><DateCompleted><Year>2010</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2015</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>13</Issue><PubDate><Year>2009</Year><Month>Oct</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.</ArticleTitle><Pagination><MedlinePgn>1941-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22679</ELocationID><Abstract><AbstractText>Our objective was to estimate the effect of atypical antipsychotics (AAs) on the rate of fractures in a parkinsonism population. We conducted an age- and state-matched nested case-control study in five states (CA, FL, NY, OH, IL) using the Medicaid analytic extract from 2001 to 2002. Eligible participants had a diagnosis of parkinsonism, excluding persons with secondary parkinsonism, bone cancer, bone infections, schizophrenia, schizoaffective disorder, and those who used conventional antipsychotics. The primary outcome was the occurrence of a fracture of the femur, ankle, fibula, tibia, humerus, radius, or ulna (N = 851). Risk-set sampling defined controls (N = 4220). We used conditional-logistic regression to derive adjusted odds ratios (AOR) and 95% confidence intervals of the association between fracture and use of quetiapine, risperidone, or olanzapine in the 60 days before the index date compared to nonuse. After adjustment for confounding, use of quetiapine (AOR 2.4; 95% CI 1.5-3.8), risperidone (AOR 1.2; 95% CI 0.9-1.7), or olanzapine (AOR 1.7; 95% CI 1.2-2.4) was associated with a higher rate of fracture. Use of an AA was associated with a higher rate of fracture in persons with parkinsonism. Prescribers must be cautious when using these agents in elderly persons with parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dore</LastName><ForeName>David D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>i3 Drug Safety, 950 Winter Street, Suite 3800, Waltham, Massachusetts, USA. david.dore@i3drugsafety.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trivedi</LastName><ForeName>Amal N</ForeName><Initials>AN</Initials></Author><Author ValidYN="Y"><LastName>Mor</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Joseph H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Lapane</LastName><ForeName>Kate L</ForeName><Initials>KL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>5T32HS000011-21</GrantID><Acronym>HS</Acronym><Agency>AHRQ HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000369">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014150">Antipsychotic Agents</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016022">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016001">Confidence Intervals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016208">Databases, Factual</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050723">Fractures, Bone</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016015">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008484">Medicaid</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000706">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016017">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012307">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" Type="Geographic" UI="D014481">United States</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22679</ArticleId><ArticleId IdType="pubmed">19645066</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001C12 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001C12 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:19645066
|texte= Atypical antipsychotic use and risk of fracture in persons with Parkinsonism.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:19645066" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |